Be the first to review this item
Stugeron (Cinnarizine, Cinnarizinum) - selective blocker of calcium channels of Class IV. Improves cerebral, coronary and peripheral circulation; improves microcirculation.
By inhibiting flow in vascular smooth muscle cells of calcium ions, reduces the tone of smooth shell arterioles; reduces their sensitivity to vasoconstrictor biogenic substances (epinephrine, norepinephrine), bradykinin. Reduces the excitability of the vestibular apparatus. It is characterized by a high affinity for cerebral vessels. It improves the microcirculation, increasing the deformability of red blood cells and reduce the increased blood viscosity. It has a mild antihistamine activity.
Hypersensitivity to the drug. Lupus erythematosus.
Pregnancy and breast-feeding:
Despite the fact that the animal studies have not established teratogenic effects stugeron, use of the drug during pregnancy is possible only in exceptional cases where the expected benefit to the mother outweighs the potential significant risk to the fetus.
It is not known whether Cinnarizine in breast milk, therefore the use of stugeron lactation (breastfeeding) is allocated is not recommended.
In Parkinson's disease stugeron prescribed only in exceptional cases where the expected benefit significantly outweighs the potential risk.
Stugeron, due to the presence of anti-histamine effect can neutralize positive skin reaction during the diagnostic tests. In this regard, for 4 days prior to the trial medication should be canceled.
Patients taking the drug, it is forbidden to drink alcohol.
Monitoring of laboratory parameters
With prolonged use stugeron recommended to control blood laboratory parameters and indicators of liver and kidney function.
Effects on ability to drive vehicles and other machines that require high concentration of attention
Patients receiving the drug should use caution when doing activities that require increased attention and psychomotor speed reactions.
Establish individually. For optimal therapeutic dose should move gradually. The maximum daily dose - 225 mg (9 tab).
The drug should be taken after meals.
Children aged 6-12 years appoint half the dose for adults.
When violations of cerebral circulation
Adults appoint 25-50 mg 3 times / day.
When violations of the peripheral circulation
Assign to 50-75 mg 3 times / day.
When labyrinth disorders
Assign to 25 mg 3 times / day.
To prevent kinetoses
Adults appoint 25 mg over 30 minutes to travel from the re-admission every 6 hours.
From the digestive system: dyspepsia, dry mouth; in rare cases - cholestatic jaundice.
CNS: rarely - headache; in elderly patients with prolonged use stugeron possible extrapyramidal syndromes, depression (in such cases, treatment should be interrupted).
Other: allergic reactions, weight gain, increased sweating; in rare cases - lupus-like syndrome, lichen planus.
In a joint application stugeron and ethanol (or ethanol-preparations), hypotensive, neuroprotective and vasodilators, and other drugs that have a depressant effect on the central nervous system (tricyclic antidepressants, hypnotics, sedatives) noted increased their actions.
Important notice- the outer box design may vary before prior notice!
Someone from the USA - just purchased the goods:
Kartalaks 60 capsules